May 06, 2026

Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis

Caris MI Clarity leverages AI to transform how recurrence risk is understood and applied in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer IRVING, Texas, May 5, 2026 /PRNewswire/ -- Caris Life Sciences®...

recent articles

HALO® MASTERCLASS WEBINAR SERIES Indica Labs is excited to introduce our new HALO® Masterclass Webinar Series.  Each masterclass webinar will offer a deep dive into a specific module or capability within our HALO, HALO AI, HALO Link...

FDA’s Enforcement Discretion Allowing Use of ImageScope DX Viewing Software for Remote Diagnosis During COVID-19 Emergency Your safety is very important to us at Leica Biosystems. We are pleased to inform you that Aperio ImageScope DX with...

Inspirata gains strategic support in its initiative to allow pathology departments across the world to offer work-from-home opportunities for their pathologists during the COVID-19 pandemic crisis. Tampa, Florida (GLOBE NEWSWIRE) -- Cancer...

7 research projects (investigating cancer, neurodegenerative, and liver diseases) spanning 4 countries (Norway, Finland, the Netherlands, and the US) are all currently underway in the aiForward program. Created and run by Aiforia, the aiForward...

OR

platinum partners

gold partners

Silver Partners

Media Partners